Search research articles
Contact Us
Filters
Showing results (51-60 of 66) with videos related to
Page
of 7
Sort By:
Molecular Pharmaceutics
|
April 18, 2020
Ultrasound Enhances ZD2767P-Carboxypeptidase G2 against Chemoresistant Ovarian Cancer Cells by Altering the Intracellular Pharmacokinetics of ZD2767D
Qianfen Liu, Xiaocui Zhong, Ying Zhang, et al.
ACS Medicinal Chemistry Letters
|
May 15, 2024
Intracellular Pharmacokinetics of Activated Drugs in a Prodrug-Enzyme-Ultrasound System: Evaluations on ZD2767P+CPG2+US
Tinghe Yu, Xinya Li, Tianran Yu, et al.
Oncology Letters
|
September 23, 2020
Erratum: DR2 blocker thioridazine: A promising drug for ovarian cancer therapy
Min Yong, Tinghe Yu, Si Tian, et al.
Oncology Letters
|
January 19, 2018
DR2 blocker thioridazine: A promising drug for ovarian cancer therapy
Min Yong, Tinghe Yu, Si Tian, et al.
Endocrine-Related Cancer
|
October 26, 2017
Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells
Biao Wan, Leheyi Dai, Li Wang, et al.
Oncology Reports
|
March 5, 2015
High level of CFTR expression is associated with tumor aggression and knockdown of CFTR suppresses proliferation of ovarian cancer in vitro and in vivo
Jiao Xu, Min Yong, Jia Li, et al.
Frontiers in Cell and Developmental Biology
|
July 19, 2021
NTNG1 Modulates Cisplatin Resistance in Epithelial Ovarian Cancer Cells via the GAS6/AXL/Akt Pathway
Shanyu Fang, Yuanyuan Luo, Ying Zhang, et al.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi = Journal of Biomedical Engineering = Shengwu Yixue Gongchengxue Zazhi
|
November 22, 2007
[Using process of refolding the protein to obtain recombinant human interleukin-1 receptor antagonist]
Shugang Li, Xiaoyan Deng, Hong Zhao, et al.
Oncology Letters
|
March 21, 2020
Erratum: DR2 blocker thioridazine: A promising drug for ovarian cancer therapy
Min Yong, Tinghe Yu, Si Tian, et al.
International Journal of Molecular Sciences
|
October 14, 2022
IDO1 Modulates the Sensitivity of Epithelial Ovarian Cancer Cells to Cisplatin through ROS/p53-Dependent Apoptosis
Houmei Wang, Yuanyuan Luo, Rui Ran, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 66) with videos related to
Sort By:
Page
of 7
Molecular Pharmaceutics
|
April 18, 2020
Ultrasound Enhances ZD2767P-Carboxypeptidase G2 against Chemoresistant Ovarian Cancer Cells by Altering the Intracellular Pharmacokinetics of ZD2767D
Qianfen Liu, Xiaocui Zhong, Ying Zhang, et al.
ACS Medicinal Chemistry Letters
|
May 15, 2024
Intracellular Pharmacokinetics of Activated Drugs in a Prodrug-Enzyme-Ultrasound System: Evaluations on ZD2767P+CPG2+US
Tinghe Yu, Xinya Li, Tianran Yu, et al.
Oncology Letters
|
September 23, 2020
Erratum: DR2 blocker thioridazine: A promising drug for ovarian cancer therapy
Min Yong, Tinghe Yu, Si Tian, et al.
Oncology Letters
|
January 19, 2018
DR2 blocker thioridazine: A promising drug for ovarian cancer therapy
Min Yong, Tinghe Yu, Si Tian, et al.
Endocrine-Related Cancer
|
October 26, 2017
Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells
Biao Wan, Leheyi Dai, Li Wang, et al.
Oncology Reports
|
March 5, 2015
High level of CFTR expression is associated with tumor aggression and knockdown of CFTR suppresses proliferation of ovarian cancer in vitro and in vivo
Jiao Xu, Min Yong, Jia Li, et al.
Frontiers in Cell and Developmental Biology
|
July 19, 2021
NTNG1 Modulates Cisplatin Resistance in Epithelial Ovarian Cancer Cells via the GAS6/AXL/Akt Pathway
Shanyu Fang, Yuanyuan Luo, Ying Zhang, et al.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi = Journal of Biomedical Engineering = Shengwu Yixue Gongchengxue Zazhi
|
November 22, 2007
[Using process of refolding the protein to obtain recombinant human interleukin-1 receptor antagonist]
Shugang Li, Xiaoyan Deng, Hong Zhao, et al.
Oncology Letters
|
March 21, 2020
Erratum: DR2 blocker thioridazine: A promising drug for ovarian cancer therapy
Min Yong, Tinghe Yu, Si Tian, et al.
International Journal of Molecular Sciences
|
October 14, 2022
IDO1 Modulates the Sensitivity of Epithelial Ovarian Cancer Cells to Cisplatin through ROS/p53-Dependent Apoptosis
Houmei Wang, Yuanyuan Luo, Rui Ran, et al.
Page
of 7